Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd. is a research and development-oriented pharmaceutical company headquartered in Tokyo, Japan. The company focuses on discovering, developing, manufacturing, and marketing prescription medicines, with a strong emphasis on oncology, immunology, and specialty diseases. Chugai plays a significant role in the Japanese healthcare market and also operates internationally through overseas businesses spanning Europe and Asia. Its portfolio includes innovative biologics and antibody-based therapies, supported by proprietary technologies aimed at addressing high unmet medical needs. As a subsidiary of Roche Holding, Chugai leverages access to global pipelines while contributing its own novel compounds and antibody engineering capabilities. The company’s products are used in hospital and specialist settings, particularly for cancer treatment and autoimmune disorders, and it engages in both domestic and international clinical development and regulatory activities. Chugai’s integration of research, manufacturing, and commercialization across multiple regions positions it as a key player in the global pharmaceutical and biotechnology value chain.